Retatrutide is an investigational triple agonist that simultaneously targets GLP-1, GIP, and glucagon receptors — under clinical investigation and not FDA-approved; an approval date is not established. At My Concierge MD, Dr. David Nazarian — a board-certified internal medicine physician trained at UCLA, the Sackler School of Medicine, and Huntington Memorial Hospital, a USC-affiliated teaching institution — provides clinical consultation regarding retatrutide and other emerging weight loss therapies within a comprehensive medical weight loss program in Beverly Hills.
Initially found Dr Nazarian for medical weight loss and then found out about all the regenerative and anti aging medicine services his medical clinic offers. They have one of the best IV exosomes and exosome therapy available. They have been able to help me overcome my fatigue as welll as lose weight safely and effectively. Their semaglutide injections for weight loss has really helped me lose weight and feel so much better.
The Science Behind Retatrutide
Retatrutide is a once-weekly subcutaneous injection developed by Eli Lilly that engages three hormonal pathways central to appetite regulation, metabolism, and energy balance:
- GLP-1 (Glucagon-Like Peptide-1): Reduces appetite, slows gastric emptying, and improves glycemic control.
- GIP (Glucose-Dependent Insulinotropic Polypeptide): Enhances insulin sensitivity and complements GLP-1 in modulating food intake.
- Glucagon Receptor: Increases energy expenditure and influences hepatic fat metabolism.
Retatrutide targets three receptors, whereas semaglutide targets GLP-1 and tirzepatide targets GLP-1 and GIP. A difference in mechanism does not by itself establish superiority, and results from separate trials should not be treated as a direct comparison.
Clinical Research and Outcomes
In the published Phase 2 obesity trial, participants assigned to 12 mg retatrutide had a mean weight reduction of 24.2% at 48 weeks, compared with 2.1% with placebo. This is a study result, not a predicted outcome for an individual patient. The TRIUMPH research program includes studies in several populations:
- TRIUMPH-1: Adults with obesity without diabetes
- TRIUMPH-2: Adults with type 2 diabetes
- TRIUMPH-4: Adults with obesity and knee osteoarthritis
- TRIUMPH CVOT: Cardiovascular outcomes trial
Lilly’s December 2025 TRIUMPH-4 announcement reported a mean weight reduction of 28.7% at 68 weeks with the 12 mg dose under the efficacy estimand, in adults with obesity or overweight and knee osteoarthritis without diabetes. Study populations, analysis methods, and treatment duration matter when interpreting results. Additional Phase 3 results have since been reported; trial findings do not establish FDA approval.
Current FDA Status
Retatrutide is investigational and is not FDA-approved for any indication. FDA states that it cannot be used in compounding under federal law. An approval date cannot be promised. Patients can discuss legitimate clinical-trial eligibility and currently approved treatment alternatives with their clinician.
- Clinical trial participation: Eligible patients may be assessed for enrollment and referred to active TRIUMPH study sites.
- Treatment with FDA-approved alternatives: Eligible patients can discuss approved medicines such as tirzepatide or semaglutide. These are separate treatment options, not access to retatrutide.
How My Concierge MD Approaches Retatrutide
At My Concierge MD, retatrutide consultations are integrated into a broader medical weight loss evaluation:
- Education and Informed Decision-Making: Each consultation includes a clear discussion of retatrutide’s current FDA status, available clinical evidence, uncertainties about future approval, and lawful research access.
- Evaluation for FDA-Approved Alternatives: Eligibility for approved therapies such as tirzepatide or semaglutide depends on the patient’s medical history, indication, and contraindications.
- Clinical Trial Referral When Appropriate: Patients interested in participating in retatrutide research may be evaluated for eligibility and referred to active TRIUMPH study sites.
- Continuity for Future Transition: Treatment options can be reassessed as evidence and regulatory status evolve. Future approval, availability, and suitability cannot be assumed.
Frequently Asked Questions About Retatrutide
-
Retatrutide targets GLP-1, GIP, and glucagon receptors. Tirzepatide targets GLP-1 and GIP, and semaglutide targets GLP-1. Results from separate studies are not a direct comparison because populations, doses, durations, and analyses differ.
-
An approval date is not established. Clinical trial results and development plans do not guarantee FDA approval or commercial availability.
-
Retatrutide is not FDA-approved and cannot be used in compounding under federal law. Ask your clinician about legitimate research opportunities and their eligibility requirements. Approved medicines are separate alternatives, not a way to obtain retatrutide.
-
The published Phase 2 trial reported mean weight reduction of 24.2% with the 12 mg dose at 48 weeks versus 2.1% with placebo. Lilly’s December 2025 TRIUMPH-4 announcement reported 28.7% at 68 weeks with 12 mg under the efficacy estimand in its study population. These findings do not predict an individual’s results or establish approval.
-
Reported adverse effects include gastrointestinal symptoms and dysesthesia, an altered skin sensation. Rates vary by trial and dose. The safety profile continues to be evaluated; these examples are not a complete list of risks.
-
A medical consultation can address approved treatment options and legitimate clinical research opportunities. Any future use would depend on regulatory status, availability, and your individual medical needs.
Why Choose My Concierge MD for Retatrutide Consultation
- Physician-Led Evaluation: Consultations are conducted by Dr. David Nazarian, a board-certified internal medicine physician trained at UCLA, the Sackler School of Medicine, and Huntington Memorial Hospital — a USC-affiliated teaching institution — and a diplomate of the American Board of Internal Medicine.
- Honest Regulatory Framing: Each consultation includes a clear discussion of retatrutide’s current FDA status, available alternatives, and the uncertainty of any future approval timeline.
- Integrated Treatment Planning: Retatrutide consultations are positioned within a comprehensive medical weight loss program, with discussion of approved treatments when clinically appropriate and reassessment as evidence changes.
- Continuity Across the GLP Class: The practice maintains active treatment protocols for semaglutide and tirzepatide, allowing seamless management as the GLP-class medication landscape evolves.
Schedule a Retatrutide Consultation in Beverly Hills
Schedule a consultation with Dr. Nazarian at My Concierge MD in Beverly Hills to discuss retatrutide, currently FDA-approved alternatives, and how to develop a medical weight loss strategy aligned with both your goals and the evolving therapeutic landscape. Each evaluation is conducted with the time, depth, and direct physician access that defines the concierge medicine model — serving patients across Beverly Hills and Greater Los Angeles.
Sources: FDA regulatory information; published Phase 2 trial; Lilly TRIUMPH-4 results; Lilly development updates.
Medically reviewed by David Nazarian, MD on